" class="no-js "lang="en-US"> Alphyn Biologics Presents Data from Atopic Dermatitis Trial
Friday, June 09, 2023

Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress

Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, will present for the first time new pediatric data from its Phase 2a clinical trial of a topical candidate for mild-to-moderate atopic dermatitis (AD) at the 22nd European Society for Pediatric Dermatology Congress (ESPD), May 4-6 in Malaga, Spain. AB-101a is in development to uniquely treat the immune and bacterial components of AD in patients ages 2 through adult. This pediatric population met all of its primary clinical trial endpoints.

“Atopic dermatitis commonly arises in childhood and may become a chronic, lifelong disease,” said Alphyn CEO Neal Koller, sponsor of the research reported in the ESPD poster (P198). “We are hopeful that AB-101a will offer children and their physicians the first therapeutic for AD that treats the immune system component and the bacterial complications of AD, including those commonly associated with Staph (Staphylococcus aureus) and methicillin-resistant Staph, and has a safety profile that supports continuous, long-term use.”

In January, Alphyn Biologics reported positive results from the first cohort of its Phase 2a clinical trial of AB-101a, a non-steroid, topical AD treatment. The trial met all of its primary endpoints, highlighting its potential as a safe and effective AD treatment that may be effective for long-term continuous use. The randomized, vehicle-controlled, double-blind trial is evaluating the treatment protocol of AB-101a across multiple sites using standard scales for assessing AD.

  1. Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
  2. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
  3. Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
  4. Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
  5. Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more